Key facts
- Notable investors include Venrock, Cove Fund.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Eira Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Eira Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Eira Bio
Developer of an antibody discovery and optimization platform designed to generate therapeutic antibodies against complex, multi-pass membrane protein targets for drug development. The company offers yeast-based synthetic biology systems, continuous directed evolution workflows, and integrated antibody engineering and characterization capabilities, enabling biotechnology and pharmaceutical drug developers to access previously intractable biological targets and progress antibody therapeutics with improved feasibility, consistency, and translational potential.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2025
- Website
- eirabio.com/
- Ownership
- Privately Held (backing)
Eira Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Eira Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Eira Bio in its N-PORT filings yet. We sweep new filings monthly.